lenalidomide has been researched along with Cryptogenic Fibrosing Alveolitis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Deng, R; Gao, S; Huang, H; Jiang, Q; Li, S; Li, X; Liang, Q; Luan, J; Ruan, H; Yang, C; Zhang, F; Zhang, R; Zhou, H | 1 |
| Ai, X; Gu, X; Ji, L; Liu, H; Luo, Z; Sun, Y; Xu, X; Yang, C; Zhao, C | 1 |
2 other study(ies) available for lenalidomide and Cryptogenic Fibrosing Alveolitis
| Article | Year |
|---|---|
Lenalidomide attenuates post-inflammation pulmonary fibrosis through blocking NF-κB signaling pathway.
Topics: Bleomycin; Humans; Idiopathic Pulmonary Fibrosis; Inflammation; Lenalidomide; NF-kappa B; Signal Transduction; Transforming Growth Factor beta1 | 2022 |
Inhalation Lenalidomide-Loaded Liposome for Bleomycin-Induced Pulmonary Fibrosis Improvement.
Topics: Animals; Bleomycin; Idiopathic Pulmonary Fibrosis; Lenalidomide; Liposomes; Lung; Mice | 2023 |